Literature DB >> 11990077

Drug addiction. Part II. Neurobiology of addiction.

J Vetulani1.   

Abstract

The drug addiction may be regarded as the disease of the brain reward system. This system, closely related to the system of emotional arousal, is located predominantly in the limbic structures of the brain. Its existence was proved by demonstration of the "pleasure centers," that were discovered as location from which electrical self-stimulation is readily evoked. The main neurotransmitter involved in the reward is dopamine, but other monoamines and acetylcholine may also participate. The anatomical core of the reward system are dopaminergic neurons of the ventral tegmentum that project to the nucleus accumbens, amygdala, prefrontal cortex and other forebrain structures. Several of those structures may be specifically involved in the reward produced by different substances, when anticipating the reward. The recent discovery of CART peptides may importantly expand our knowledge about the neurochemistry of reward. Natural rewarding activities and artificial chemical rewarding stimuli act at the same locations, but while natural activities are controlled by feedback mechanisms that activate aversive centers, no such restrictions bind the responses to artificial stimuli. There are several groups of substances that activate the reward system and they may produce addiction, which in humans is a chronic, recurrent disease, characterized by absolute dominance of drug-seeking behavior. The craving induced by substances of addiction inhibits other behaviors. The adaptation of an organism to a chronic intake of drugs involves development of adaptive changes, sensitization or tolerance. It is thought that the gap between sensitization developing for the incentive value of the drug and tolerance to the reward induced by its consumption underlies the vicious circle of events leading to drug dependence. The vulnerability to addiction is dependent not only on the environment, but also on genetic factors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11990077

Source DB:  PubMed          Journal:  Pol J Pharmacol        ISSN: 1230-6002


  26 in total

1.  The endocannabinoid system modulates the valence of the emotion associated to food ingestion.

Authors:  Mónica Méndez-Díaz; Pavel Ernesto Rueda-Orozco; Alejandra Evelyn Ruiz-Contreras; Oscar Prospéro-García
Journal:  Addict Biol       Date:  2010-12-23       Impact factor: 4.280

2.  Behavioral inhibition in mice bred for high vs. low levels of methamphetamine consumption or sensitization.

Authors:  Travis M Moschak; Katherine A Stang; Tamara J Phillips; Suzanne H Mitchell
Journal:  Psychopharmacology (Berl)       Date:  2012-02-04       Impact factor: 4.530

Review 3.  Proteomic approaches and identification of novel therapeutic targets for alcoholism.

Authors:  Giorgio Gorini; R Adron Harris; R Dayne Mayfield
Journal:  Neuropsychopharmacology       Date:  2013-07-31       Impact factor: 7.853

Review 4.  Genetic factors influencing alcohol dependence.

Authors:  R D Mayfield; R A Harris; M A Schuckit
Journal:  Br J Pharmacol       Date:  2008-03-24       Impact factor: 8.739

5.  Neonatal quinpirole treatment enhances locomotor activation and dopamine release in the nucleus accumbens core in response to amphetamine treatment in adulthood.

Authors:  Zackary A Cope; Kimberly N Huggins; A Brianna Sheppard; Daniel M Noel; David S Roane; Russell W Brown
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

6.  An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats.

Authors:  L Antkiewicz-Michaluk; M Filip; J Michaluk; I Romańska; E Przegaliński; J Vetulani
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

7.  Gene expression differences in mice divergently selected for methamphetamine sensitivity.

Authors:  Abraham A Palmer; Miguel Verbitsky; Rathi Suresh; Helen M Kamens; Cheryl L Reed; Na Li; Sue Burkhart-Kasch; Carrie S McKinnon; John K Belknap; T Conrad Gilliam; Tamara J Phillips
Journal:  Mamm Genome       Date:  2005-05       Impact factor: 2.957

Review 8.  A possible physiological role for cerebral tetrahydroisoquinolines.

Authors:  Jerzy Vetulani; Lucyna Antkiewicz-Michaluk; Irena Nalepa; Mario Sansone
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 9.  Does the difference between physically active and couch potato lie in the dopamine system?

Authors:  Amy M Knab; J Timothy Lightfoot
Journal:  Int J Biol Sci       Date:  2010-03-09       Impact factor: 6.580

Review 10.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.